3-(benzoxazole-2-yloxy)-1-butyl-5,6-dimethyl-1H-pyridine-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(benzoxazole-2-yloxy)-1-butyl-5,6-dimethyl-1H-pyridine-2-one
• 英文别名: 3-(1,3-Benzoxazol-2-yloxy)-1-butyl-5,6-dimethylpyridin-2-one
• 化学式: C₁₈H₂₀N₂O₃
• 分子量: 312.368
• InChiKey: ZCGSTANOPYTMJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  ethyl 3-(N-benzyl-2-methoxyacetamido)-2-methylbut-2-enoate 在 palladium 10% on activated carbon 、 氢气 、 sodium ethanolate 、 吡啶盐酸盐 、 sodium hydride 、 potassium carbonate 、 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 正丁醇 为溶剂， 200.0 ℃ 、500.01 kPa 条件下， 反应 101.5h， 生成 3-(benzoxazole-2-yloxy)-1-butyl-5,6-dimethyl-1H-pyridine-2-one
  参考文献：
  名称：

  Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists

  摘要：

  Selective CB2 agonists have the potential for treating pain without central CBI-mediated adverse effects. Screening efforts identified 1,2-dihydro-3-isoquinolone 1; however, this compound has the drawbacks of being difficult to synthesize with two asymmetric carbons on an isoquinolone scaffold and of having a highly lipophilic physicochemical property. To address these two major problems, we designed the 2-pyridone-based lead 15a, which showed moderate affinity for CB2. Optimization of 15a led to identification of 39f with high affinity for CB2 and selectivity over CBI. Prediction of the binding mode of 39f in complex with an active-state CB2 homology model provided structural insights into its high affinity for CB2. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.006

文献信息

• Antipruritics
  申请人：Yasui Kiyoshi

  公开号：US20050101590A1

  公开（公告）日：2005-05-12

  It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.

  这意味着它旨在提供止痒药（用于控制瘙痒的药物，抗瘙痒剂和止痒药）。研究发现，具有激动性作用的大麻素受体的化合物具有止痒效果。
• Pyridone derivatives having affinity for cannabinoid 2-type receptor
  申请人：——

  公开号：US20040082619A1

  公开（公告）日：2004-04-29

  It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): 1 wherein R 1 is a group represented by the formula: —Y 1 —Y 2 —Y 3 —R a wherein Y 1 is single bond or the like; Y 2 is —C(═O)—NH— or the like; Y 3 is optionally substituted aryl or the like; R 2 is hydrogen or the like; R 3 is alkyl or the like; R 4 is alkyl or the like; R 5 is optionally substituted alkyl or the like; or R 3 and R 4 taken together with the adjacent atom form cyclic group or the like.

  发现具有与cannabinoid 2型受体结合活性的化合物，其代表式为（I）：1其中R1是由式表示的基团：—Y1—Y2—Y3—Ra其中Y1是单键或类似物；Y2是—C(═O)—NH—或类似物；Y3是可选取代芳基或类似物；R2是氢或类似物；R3是烷基或类似物；R4是烷基或类似物；R5是可选取代烷基或类似物；或R3和R4与相邻原子结合形成环状基团或类似物。
• Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
  申请人：Tada Yukio

  公开号：US20060052411A1

  公开（公告）日：2006-03-09

  It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R 1 is a group represented by the formula: —Y 1 —Y 2 —Y 3 —R a wherein Y 1 is single bond or the like; Y 2 is —C(═O)—NH— or the like; Y 3 is optionally substituted aryl or the like; R 2 is hydrogen or the like; R 3 is alkyl or the like; R 4 is alkyl or the like; R 5 is optionally substituted alkyl or the like; or R 3 and R 4 taken together with the adjacent atom form cyclic group or the like.

  被发现的化合物具有与cannabinoid type 2 受体结合活性，其化学式为(I)，其中R1是由公式表示的基团：—Y1—Y2—Y3—Ra，其中Y1是单键或类似物；Y2是—C(═O)—NH—或类似物；Y3是可选择取代的芳基或类似物；R2是氢或类似物；R3是烷基或类似物；R4是烷基或类似物；R5是可选择取代的烷基或类似物；或R3和R4与相邻原子一起形成环状基团或类似物。
• Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter
  申请人：TADA Yukio

  公开号：US20100081686A1

  公开（公告）日：2010-04-01

  It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R 1 is a group represented by the formula: —Y 1 —Y 2 —Y 3 —R a wherein Y 1 is single bond or the like; Y 2 is —C(═O)—NH— or the like; Y 3 is optionally substituted aryl or the like; R 2 is hydrogen or the like; R 3 is alkyl or the like; R 4 is alkyl or the like; R 5 is optionally substituted alkyl or the like; or R 3 and R 4 taken together with the adjacent atom form cyclic group or the like.

  发现化合物具有与cannabinoid type 2受体结合活性，该化合物的公式为（I）：其中R1是由公式表示的基团：—Y1—Y2—Y3—Ra，其中Y1是单键或类似物；Y2是—C（═O）—NH—或类似物；Y3是可选择的取代芳基或类似物；R2是氢或类似物；R3是烷基或类似物；R4是烷基或类似物；R5是可选择的取代烷基或类似物；或R3和R4与相邻原子结合形成环状基团或类似物。
• PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1357111A1

  公开（公告）日：2003-10-29

  It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R' is a group represented by the formula: -Y1-Y2-Y3Ra wherein Y1 is single bond or the like; Y2 is -C(=O)-NH- or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.

  研究发现，对大麻素 2 型受体具有结合活性的化合物由式(I)表示： 其中 R' 是由式表示的基团：-其中 Y1 是单键或类似物；Y2 是-C(=O)-NH- 或类似物；Y3 是任选取代的芳基或类似物；R2 是氢或类似物；R3 是烷基或类似物；R4 是烷基或类似物；R5 是任选取代的烷基或类似物；或 R3 和 R4 与相邻原子一起形成环状基团或类似物。